Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
doi: 10.1016/j.ejcb.2019.151058 200 LuYZhuYFengSCongQChenSZengYet al
Glucagon-like peptide-1 receptor agonists improve metabolic dysfunction-associated steatotic liver disease outcomes
In the key Phase 3 ATTAIN-1 trial published in the New England Journal of Medicine in 2025, once-daily orforglipron 36 mg produced mean body weight reductions of 11.2% at 72 weeks in adults with obesity, with nearly 55% of participants achieving at least 10% weight loss and 36% achieving 15% or more
Regulation of bone health through physical exercise: Mechanisms and types
The uptake rate of Rho123 was markedly lower in the mitochondria pre-treated with colistin than that in the untreated mitochondria (slope 0.29 vs 0.57, P = 0.0005), indicating that colistin induced the depolarization of the mitochondrial inner membrane
